Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3164
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within San Antonio, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 769–780 of 3,164 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Terminated Phase 3 Interventional

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

NCT06527404
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Interventions
AOC-1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Orange, California • Palo Alto, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Completed Phase 1Phase 2 Interventional

The Anesthetic and Analgesic Effect of Adjunct Liposomal Bupivacaine in Periodontal Surgical Procedures

NCT07725731
View directory record Official record
Conditions
Periodontal Surgery
Interventions
0.5% Bupivacaine HCl, Liposomal Bupivacaine (EXPAREL®)/Bupivacaine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
24
States / cities
Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Completed Phase 3 Interventional Results available

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

NCT03223753
View directory record Official record
Conditions
Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Educational Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
Children's Oncology Group
Network
Eligibility
8 Years to 16 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
113
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

NCT00379340
View directory record Official record
Conditions
Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
3-Dimensional Conformal Radiation Therapy, Conventional Surgery, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Vincristine Sulfate Liposome
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
199
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

NCT03975647
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
tucatinib, placebo, T-DM1
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
321
States / cities
Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

NCT03523858
View directory record Official record
Conditions
Progressive Multiple Sclerosis (PMS)
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
15
States / cities
Laguna Hills, California • Pasadena, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Completed Early Phase 1 Interventional

Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery

NCT05971173
View directory record Official record
Conditions
Hip Fractures
Interventions
Juven, Centrum Silver 50+
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Recruiting Not applicable Interventional

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

NCT02744677
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions
SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

NCT05609370
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions
Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 15, 2026, 1:32 PM EST
Not yet recruiting Phase 1 Interventional

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

NCT07707674
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
XNW28012
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Detroit, Michigan • Grand Rapids, Michigan • Lake Success, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 15, 2026, 1:32 PM EST